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Purpose: Currently available ocular moisture chambers are not adequate to manage the treatment 
of periocular burns, corneal injuries, and infection. The purpose of these studies was to demon-
strate that a flexible, semi-transparent ocular wound chamber device adapted from technology 
currently used on dermal wounds is safe for use on corneal epithelial injuries.
Materials and methods: A depilatory cream (Nair™, 30 seconds) was utilized to remove 
the excess hair surrounding the left eyes of anesthetized Institute Armand Frappier (IAF) hair-
less, female guinea pigs (Crl:HA-Hrhr). A 4 mm corneal epithelium defect was created using 
a corneal rust ring remover (Algerbrush®II). Epithelial defects were either left untreated or the 
eyes were fitted with an ocular wound chamber and 0.5 mL of hydroxypropyl methylcellulose 
(HPMC) gel (GenTeal®) or HPMC liquid (GenTeal®) was injected into each chamber (N=5 per 
group). At 0, 24, 48, and 72 hours fluorescein and optical coherence tomography imaging was 
collected and the intraocular pressure (IOP) was measured. H&E staining was performed on 
corneal and eyelid skin samples and evaluated by a veterinary pathologist.
Results: Corneal epithelial wounds demonstrated 100% closure rates when left untreated or 
treated with an ocular wound chamber containing HPMC gel at 72 hours while wounds treated 
with an ocular wound chamber containing HPMC liquid were 98% healed. No significant 
differences were found in corneal thickness and wound healing, IOP, or eyelid skin pathology 
in any treatment group when compared to controls.
Conclusions: This study indicates that adapted wound chamber technology can be safely used 
on sterile, corneal epithelial wounds without adverse effects on periocular or ocular tissue when 
filled with a liquid or gel.
Keywords: corneal epithelial wound healing, periocular burns, wound chamber, exposure 
keratopathy, guinea pig
Introduction
Between 7.5% and 27% of patients with facial burns experience some ocular trauma 
secondary to the initial burn injury such as exposure keratopathy or subsequent 
infection.1,2 Exposure keratopathy, which has been observed in up to 60% of ICU 
patients,3,4 occurs when the ocular surface is exposed to the environment for an 
extended length of time such as when the eyelids are damaged and unable to close or 
provide adequate ocular coverage. This exposure may subsequently lead to corneal 
epithelial damage or PCEDs, defects that fail to heal over a 2-week period.5 If PCEDs 
are not effectively treated, corneal ulceration, scarring, and, in more severe cases, 
partial or complete vision loss can occur.6 In the presence of even minor defects, 
intensive treatment including the administration of hourly drops should be initiated.2 
As ophthalmic drops rapidly dissipate after administration, therapies that involve the 
frequent administration of drops require a high burden of care and patient compliance. 
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Other therapeutic options for patients suffering from expo-
sure keratopathy include bandage or scleral contact lenses7 
and the use of more invasive surgical interventions which 
are amniotic membrane grafting7,8 or tarsorrhaphy.7 Current 
therapies tend to be ineffective thereby prolonging healing 
time and a patient’s impaired visual acuity.7 Due to the 
challenges encountered in treating these patients, clinicians 
require more effective treatment modalities for the manage-
ment of persistent corneal epithelial defects.
The cornea is comprised of five well-characterized lay-
ers from the anterior to the posterior region, respectively: 
epithelium, Bowman’s layer, stroma, Descement’s membrane, 
and endothelium.9 As the outermost layer of the cornea, the 
epithelium provides an important protective barrier to the rest 
of the eye against noxious environmental stimuli and inflam-
matory mediators in the tear film. Furthermore, a smooth 
epithelial surface is essential for proper light refraction and 
consequently, proper vision.10 If the corneal epithelium is com-
promised, not only is visual acuity impacted, but the cornea is 
also susceptible to infection.11 Therefore, increasing the rate 
of re-epithelialization can decrease the likelihood that patients 
will develop an ocular infection or other complications such 
as corneal melting. To this end, ocular therapies often seek to 
enhance corneal epithelial wound closure by modulating cel-
lular proliferation, migration, and adhesion.13 As a result of the 
need for therapies to treat these defects and provide protection 
to the eye, we have begun exploring therapies to address the 
clinical challenges associated with treating patients suffering 
from epithelial defects and/or keratitis infections secondary to 
corneal trauma. We aim to explore novel ophthalmic treatment 
modalities to meet the needs of both clinicians and patients.
In this study, we investigated the use of an OWC device 
adapted from a PWD currently used in dermal burn patients 
to protect the eye and facilitate corneal wound closure.14–16 
Comprised of a flexible adhesive base that attaches to the 
perimeter of the eye and enclosed by a transparent cover, 
the OWC provides protection from the external environ-
ment while allowing for visual monitoring of injured tissues 
(Figure 1). The PWD supports a fluid-filled environment 
to protect healing skin wounds while consistently deliver-
ing precise volumes and concentrations of therapeutics 
such as antibiotics. Previous studies have shown that the 
utilization of the PWD to deliver concentrated amounts of 
antibiotics to infected dermal wounds resulted in decreased 
bacterial loads and a significant reduction in inflammatory 
mediators.17,18 As a result of the success of the PWD on 
dermal wounds, OWC technology was adapted to provide a 
novel treatment for facial burn patients while providing ocular 
protection and promoting healing and re-epithelialization 
of the ocular surface. Analyses of multiple randomized, 
controlled trials have demonstrated the use of commercially 
available ocular moisture chambers in conjunction with lubri-
cating ointments such as mineral oil and petrolatum-based 
ointments are more effective at preventing exposure ker-
atopathy than lubricants and eyelid taping alone.3,4 Currently 
available moisture chambers, however, do not hold sufficient 
volumes of fluid to cover the eye and tissues as they neither 
provide a watertight seal nor are they capable of delivering 
precise and continuous doses of therapeutics to the injured 
tissue. As a result, we hypothesized that our adapted OWC 
device would provide enough fluid to cover the eye and 
periocular tissues allowing for a more advanced treatment 
for exposure keratopathy, PCEDs, and periocular burns while 
protecting the periorbital tissue and ocular surface in cases 
of facial burns that result in insufficient eyelid coverage. 
If successful, the adapted OWC would decrease the risk of 
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Figure 1 An OWC measuring 3 cm in diameter has been developed for ocular use with a flexible base that attaches to the perimeter of the eye (A). The device has a 
transparent cover and a self-sealing port that allows for the delivery of therapeutics (A). The OWC has been specifically designed for use in our guinea pig model (B) and 
provides a watertight seal that allows for the creation of a controlled microenvironment over the eye. The base, cover, and self-sealing port are labeled accordingly as 
indicated by arrows (B).
Abbreviation: OWC, ocular wound chamber.
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ocular infection and exposure keratopathy while allowing 
periocular tissues time to heal accordingly.
Material and methods
animals
Female IAF hairless, guinea pigs (200–250 g; Crl:HA-Hrhr) 
were obtained from Charles River Laboratories (Wilmington, 
MA, USA). Guinea pigs were acclimated 72 hours prior to 
experimentation and procedures performed on anesthetized 
guinea pigs. Research was conducted in compliance with 
the Animal Welfare Act, the implementing Animal Welfare 
Regulations, and the principles of the Guide for the Care and 
Use of Laboratory Animals, National Research Council. The 
facility’s IACUC approved all research conducted in this 
study. The facility where this research was conducted is fully 
accredited by Association for Assessment and Accreditation 
of Laboratory Animal Care International.
in vivo corneal wound creation
Prior to the creation of the corneal epithelial defect, isoflu-
rane titrated to 5% with oxygen was administered for 2 min 
before the administration of ketamine (Ketacine™ HCl, 
20–40 mg/kg; VetOne®, Boise, ID, USA) and dexmedeto-
midine hydrochloride (0.5 mg/kg; Putney®, Overland Park, 
KS, USA). The corneal epithelium was removed from the 
left eyes of anesthetized guinea pigs using a corneal rust 
ring remover (Algerbrush®II; Alger Company Inc., Lago 
Vista, TX, USA) as previously described while right eyes 
were uninjured and served as controls.19 Briefly, corneal 
epithelial defects were created centrally by demarcating 
the cornea using a 4 mm, disposable biopsy punch (Miltex, 
York, PA, USA) and removing the epithelium with a corneal 
rust ring remover equipped with a 1 mm rotating burr. The 
corneal epithelial defects were rinsed with sterile BSS 
(Alcon, Fort Worth, TX, USA) and stained with fluorescein 
utilizing fluorescein sodium ophthalmic strips (Fluorets; 
Laboratoire Chauvin, Aubenas, France), dampened with 
100 μL sterile BSS. Uptake of fluorescein staining was visu-
alized using a surgical microscope equipped with a cobalt 
blue filter and camera (Lumera 700; Carl Zeiss Surgical, 
Oberkochen, Germany). Images were obtained at 0, 24, 48, 
and 72 hours post injury immediately following staining 
with fluorescein. The area of each corneal epithelial defect 
was measured and quantitated using ImageJ software (U.S. 
National Institutes of Health, Bethesda, MD, USA). The 
area of each wound was expressed as a percentage of the 
original wound size. The results are reported as percent 
wound closure and mean ± SEM of five guinea pigs per 
group. Upon completion of all procedures, anesthesia was 
reversed using atipamezole hydrochloride (0.5 mg/kg; 
Orion Pharma, Espoo, Finland) at a dose equal to the dex-
medetomidine administered.
Ocular wound chamber placement
Before corneal epithelial defect creation and chamber place-
ment, the left eyes of guinea pigs were protected with a 
petrolatum and mineral oil ointment (Larci-Lube®; Allergan, 
Parsippany-Troy Hills, NJ, USA) and excess hair removed 
with a depilatory cream (Nair™, 30 seconds). The skin was 
rinsed with BSS and cleaned with 70% ethanol. Animals 
were fitted with the OWC (Applied Tissue Technologies, 
Hingham, MA, USA) (Figure 1A) over the wounded left eye 
of the guinea pig (Figure 1B). Guinea pigs were randomly 
grouped (N=5 per group) and 0.5 mL of HPMC liquid 
(GenTeal Lubricant Eye Drops Moderate Dry Eye Relief; 
Novartis Pharmaceuticals Corporation, East Hanover, NJ, 
USA) or HPMC gel (GenTeal Lubricant Eye Gel Severe 
Dry Eye Relief; Novartis Pharmaceuticals Corporation, East 
Hanover, NJ, USA) was injected into the chamber through 
a self-sealing attached port using a 25 gauge 1″ needle. One 
group of injured animals received no chamber or additional 
treatment. The chambers were replaced daily and filled 
with fresh HPMC liquid or HPMC gel. Both injured and 
uninjured eyes were assessed daily at 0, 24, 48, and 72 hour 
post chamber placement with tonometry for IOP, OCT for 
corneal thickness, white light, and fluorescein imaging for 
epithelial defects.
rebound tonometry
A tonometer (Icare®; TonoLab, Finland) was used to take an 
average of five independent IOP measurements at 0, 24, 48, 
and 72 hours while animals were under anesthesia. Measure-
ments were taken pre- and postwound creation. Results are 
presented as mean ± SEM of five guinea pigs per group.
Optical coherence tomography
Spectral Domain Optical Coherence Tomography (SD-OCT) 
(Micron IV; Phoenix Research Laboratories, Pleasanton, 
CA, USA) corneal images of wounded and control eyes 
were obtained via integrated image acquisition software 
(Phoenix Research Laboratories) for each animal at 0, 24, 
48, and 72 hours. Central corneal thickness was measured 
using ImageJ analysis software (NIH, Bethesda, MD, USA). 
Results are presented as mean ± SEM of five guinea pigs 
per group.
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histology
Following humane euthanasia, whole eye globes and skin 
samples from both wounded and control animals were col-
lected for histology at 72 hours. Whole globes were placed 
in modified Davidson’s solution (Poly Scientific R&D 
Corporation, Bay Shore, NY, USA) immediately following 
tissue collection for 24 hours for the initial fixation and then 
transferred to 10% NBF (Thermo Fisher Scientific, Middle-
town, VA, USA). Vertically bisected globes were placed 
(cut side down) in a megatissue cassette (Fisher Scientific, 
Fair Lawn, NJ, USA). Upper and lower eyelids skin samples 
(including sections of skin contacted with the wound chamber 
adhesive) were placed in 10% NBF. Eye and skin samples 
were processed, embedded in paraffin, sectioned at 4 μm 
and stained with H&E (Fisher Scientific, Fair Lawn, NJ, 
USA) according to manufacturer’s directions. Histological 
sections were scored by a board certified veterinary patholo-
gist using a scoring system created in-house as described 
in Table 1. Gradations of neovascularization, keratitis, and 
uveitis/conjunctivitis were determined for cornea samples 
while dermal inflammation, epithelial hyperplasia, and the 
presence or absence of pustules and folliculitis were identified 
in skin sections. Total number of epithelial mitotic figures 
were counted from limbus to limbus on cornea sections.
statistical analysis
Statistics were calculated and graphed using GraphPad 
Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA). 
Wound healing, corneal thickness, and IOP data were analyzed 
using two-way ANOVA followed by a Bonferroni’s multiple 
comparisons test. Pathology scores were analyzed using the 
nonparametric Kruskal–Wallis test. Independent values are 
represented as the mean ± SEM. A P-value of ,0.05 was 
regarded as significant for all statistical analyses.
Results
Corneal epithelial wound healing
To investigate the ability of corneal epithelial defects to heal 
in a fluid filled environment, corneal epithelial wounds were 
created, left uncovered or covered with an ocular wound 
chamber and filled with either HPMC gel or HPMC liquid. 
The wounds were monitored by white light imaging to visu-
ally observe any areas of corneal opacity (Figure 2A) while 
epithelial closure was monitored via fluorescein uptake for 
all animal groups (Figure 2B). Untreated corneal epithelial 
wounds were 83% re-epithelialized at 24 hours while corneal 
wounds treated with the ocular wound chamber filled with 
HPMC gel were 81% re-epithelialized and those treated 
with HPMC liquid were 71% re-epithelialized (Figure 2C). 
At 48 hours post wound creation, wounds were 99%, 100%, 
and 87% re-epithelialized when left untreated or treated with 
an OWC in conjunction with HPMC gel or HPMC liquid 
respectively. By 72 hours postwounding, nontreated injuries 
and HPMC gel were found to be 100% re-epithelialized 
while HPMC liquid treated wounds were shown to be 98% 
re-epithelialized.
Corneal thickness
To assess the response of injured corneas to prolonged liquid 
exposure and monitor changes in corneal thickness, OCT was 
employed. At each time point, OCT images were collected 
on injured eyes and the corneal thickness was measured 
(Figure 3A). Immediately after injury, no differences in 
corneal thickness were observed among groups indicating 
consistency in injury creation (Figure 3B). By 24 hour 
postinjury, all injured groups exhibited significant (P,0.05) 
increases in corneal thickening compared to the uninjured 
controls (Figure 3B). The HPMC liquid group showed con-
tinued corneal swelling at 48 hours compared to all other 
groups, while the no chamber and HPMC gel groups were 
stabilized and at 72 hours, they began to decrease.
iOP
IOP was measured to detect changes in pressure as a result 
of injury, chamber placement, and therapeutic applica-
tion. Preinjury, combined guinea pigs averaged an IOP of 
10.19 ± 0.43 mmHg (mean ± SEM). Immediate postinjury IOP 
Table 1 Pathology scoring system
Cornea
Neovascularization/
uveitis/conjunctivitis
Keratitis Epithelial 
mitotic figures
0 – absent 0 – none number of 
mitotic figures 
counted limbus 
to limbus
1 – Present 1 – Minimal
2 – Mild
3 – Moderate
4 – Marked
Skin
Dermal 
inflammation
Epithelial 
hyperplasia
Pustules/
folliculitis
0 – none 0 – none 0 – absent
1 – Minimal 1 – Mild (2× normal 
thickness)
1 – Present
2 – Mild 2 – Moderate (3–5× 
normal thickness)
3 – Moderate 3 – Marked (.5× 
normal thickness)
4 – Marked
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measurements revealed an average IOP of 11.20 ± 1.07 mmHg 
in uninjured control animals, and 10.93 ± 0.55 mmHg in the 
injured groups. By 72 hours postwounding, the IOP of treat-
ment animals containing either HPMC gel or liquid averaged 
10.20 ± 0.20 mmHg and 10.40 ± 1.03 mmHg, respectively 
(Figure 4). Overall, no significant changes in IOP measure-
ments were observed between the groups tested over time or 
as a result of injury or applied therapeutics.
eye histology
To histologically evaluate the effects of corneal injury 
creation, chamber placement, and HPMC gel and liquid 
application on the eyes, whole globes were collected at the 
time of humane euthanasia and submitted for pathology. 
H&E stained corneal sections (Figure 5A) were scored by 
a blinded veterinary pathologist utilizing a scoring matrix. 
Each sample received a score as described in Table 1 
(Figure 5B). Evidence of neovascularization, keratitis, and 
uveitis/conjunctivitis was observed in corneal sections of 
most injured groups; however, the clinical significance 
was negligible. The presence of epithelial mitotic figures 
in injured cornea sections indicated increased cellular pro-
liferation and re-epithelialization and was not significantly 
different among injured groups (Figure 5C).
skin histology
Skin eyelid histological samples were assessed by a 
veterinary pathologist to identify inflammation and epithe-
lial hyperplasia due to chamber placement and therapeutic 
application (Figure 6A). The HPMC gel group showed a 
significant increase in dermal inflammation as indicated by 
the infiltration of heterophils (P,0.02) compared to the no 
chamber group and a significant increase in epithelial hyper-
plasia (P,0.005) compared to no chamber and HPMC liquid 
animal groups (Figure 6B). No significant differences were 
observed in the histological sections in pustule formation or 
folliculitis across the groups.
Discussion
As current therapeutic options for periocular burns, corneal 
injuries, and subsequent infection are limited, improved and 
effective treatments and/or technologies are needed for the 
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management of these injuries. One therapy that has been uti-
lized to treat these types of injuries is the moisture chamber.20 
Moisture chambers are designed to increase the humidity of 
the ocular surface to treat ocular conditions such as dry eye 
syndrome, exposure keratopathy, and lagophthalmos.20,21 
While moisture chambers increase the humidity surrounding 
injured tissues, unlike the OWC, moisture chambers do not 
provide a watertight seal. This watertight seal is a critical 
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feature of the OWC that allows for increased contact time of 
therapeutics on the ocular surface. This not only allows for 
the constant delivery of therapeutics, but also protects the eye 
when the eyelids are not capable of covering the surface of 
the eye. In addition to this, the constant therapeutic delivery 
that the watertight seal provides reduces the labor of ancil-
lary hospital personnel by eliminating the need for manual 
drop instillation.
The results from this study demonstrate that existing 
PWD technology can be adapted for use on the injured ocular 
surface and uninjured periorbital tissues. Through the utili-
zation of an in vivo guinea pig model of corneal epithelial 
wound healing, we found that corneal epithelial wounds in 
all treatment groups re-epithelialized by 72 hours post injury 
as determined by fluorescein uptake (Figure 1A). Further-
more, no clinically relevant corneal or dermal pathology was 
associated with short-term OWC use in this animal model. 
This suggests that it may be feasible to safely use the OWC 
on an injured ocular surface as a novel ophthalmic treat-
ment option.
Initial studies performed by our lab using the OWC were 
aimed at testing this device on the uninjured eye (manu-
script under review). As the corneal epithelium is crucial to 
the health of the cornea, this study was designed to assess 
how corneal re-epithelialization occurs in the fluid-filled 
environment provided by the OWC. When the corneal 
epithelium is absent, the ocular surface is compromised and 
fluid enters the cornea resulting in stromal edema.12 If the 
corneal epithelium has been debrided in its entirety, stromal 
edema can persist up to 6 weeks after the initial epithelial 
injury has healed,12 typically within 48–72 hours post injury. 
In the current study, corneal thickness significantly increased 
at 24 hours after injury in all treatment groups as expected 
due to the corneal defect. After the epithelium was restored, 
around 48 hours, changes in corneal thickness were not 
significantly different from the uninjured, control corneas 
with the exception of those treated with HPMC liquid. The 
significant increase in corneal thickness persisted up to 
72 hours post injury. While some corneal swelling is con-
sidered to be normal when an epithelial injury occurs, these 
results suggest that the properties of pharmaceuticals utilized 
in the OWC such as a liquid versus a gel could have varying 
effects on the cornea.
The OWC provides an environment that allows sustained 
delivery of therapeutics, while keeping the eye moisturized 
with the clinician’s choice of solution or lubricant to include 
artificial tears. Artificial tears come in a variety of formula-
tions including PVA, SH, CMC, HPMC (HMC), HP guar, 
and oil-based tears. The type of artificial tear used largely 
depends on the needs of the patient. When artificial tears 
or ophthalmic drops are utilized as a therapeutic, the drops 
quickly dissipate after administration. The ultimate goal is 
to correct the imbalance in the tear film, which is comprised 
of three layers: the mucin, aqueous, and lipid layer. Imbal-
ances in any layer of the tear film can result in diseases such 
as dry eye or exposure keratopathy.22 When treating these 
patients, it may be important to consider the properties of the 
selected artificial tears and solutions delivered in the OWC 
as they may contribute to corneal swelling as observed in 
our previous studies utilizing BSS in the OWC (manuscript 
in preparation). When BSS was placed in the OWC, corneas 
demonstrated increased swelling when compared to those 
treated with HPMC. The results from this study and our 
previous studies indicate that a more viscous solution or gel 
such as HPMC may prove to be the most beneficial. Overall, 
while it appears to be safe to treat eyes with corneal epithelial 
defects with the OWC, these results indicate the importance 
of applying the most optimal solution and/or lubricant for 
use in the OWC.
Given that previous studies have investigated PWD 
technology and have shown that it allows for the application 
of increased concentrations and sustained delivery of antibi-
otics to the surface of the wound;17 it is conceivable that this 
technology would allow for a decrease in the sterilization 
time of the ocular surface, thereby decreasing the risk of 
infection and subsequent vision loss. Future studies will be 
expanded to determine if the adapted OWC technology can 
be employed successfully to treat injured periorbital tissue, 
prevent exposure keratopathy, and manage ocular infections.
Conclusion
The data collected in this study demonstrate that our OWC 
device is safe on sterile, corneal epithelial wounds when 
filled with HPMC gel or liquid. While not significantly 
different, our results also suggest that the vehicle utilized 
in the chamber in the presence of an epithelial defect be 
carefully considered as HPMC liquid-treated eyes appeared 
to heal more slowly. Furthermore, eyes treated with HPMC 
liquid showed significant corneal thickening compared to 
eyes treated with HPMC gel at 48 hours, but the difference 
between these two groups decreased and was no longer 
significant by 72 hours. Overall, these studies lend that the 
use of the OWC device is safe on the skin surrounding the 
eye and that OWC use does not affect corneal epithelial 
wound healing when HPMC gel is utilized. Further studies 
are needed to determine if this device can successfully treat 
other ocular disparities such as exposure keratopathy, ocular 
infections, and injured or burned periorbital tissues.
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